Jpmorgan Chase & CO Fulcrum Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 79,120 shares of FULC stock, worth $293,535. This represents 0.0% of its overall portfolio holdings.
Number of Shares
79,120
Previous 187,163
57.73%
Holding current value
$293,535
Previous $668,000
44.46%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding FULC
# of Institutions
142Shares Held
48.8MCall Options Held
6.8MPut Options Held
1.73M-
Ra Capital Management, L.P. Boston, MA10.2MShares$37.9 Million0.51% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$19.5 Million2.43% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$17.8 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.78MShares$17.7 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.25MShares$12.1 Million0.0% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $193M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...